Sirtex Medical provides collaboration update with Oncosec

• Sirtex Medical US Holdings announces an advancement in its strategic collaboration with OncoSec Medical (NASDAQ:ONCS) relating to OncoSec's lead product candidate TAVO (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
• The update provides Sirtex with the option to acquire the right to co-promote TAVO and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma.
• Last year, Sirtex acquired an equity stake in OncoSec and entered an arrangement to assist OncoSec with pre-marketing activities for TAVO and its Visceral Lesion Applicator (VLA) product in exchange for a low single-digit royalty.